Thiopental
(AWLILQARPMWUHA-UHFFFAOYSA-M)
Structure
- SMILES
- CCCC(C1(CC)C(=O)NC(=NC1=O)[S-])C.[Na+]
- Molecular Formula:
- C11H17N2NaO2S
- Molecular Weight:
- 264.320
- Log P:
- 1.1427
- Hydrogen Bond Acceptor:
- 5
- Hydrogen Bond Donor:
- 1
- TPSA:
- 58.53
- CAS Number(s):
- 71-73-8
Synonym(s)
1.
Thiopental
2.
Penthiobarbital
3.
Thiomebumal
4.
Thiopentobarbital
5.
Bomathal
6.
Nesdonal
7.
Pentothal
8.
Pentothal Sodico
9.
Sodipental
10.
Thionembutal
11.
Thiopental Nycomed
12.
Thiopental Sodium
13.
Thiopentone
14.
Tiobarbital Braun
15.
Trapanal
External Link(s)
Adverse Drug Event(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Drug ineffective | FAERS: 5 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 2 | Cardiac Arrest | FAERS: 4 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 3 | Completed Suicide | FAERS: 3 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 4 | Hypotension | FAERS: 3 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 5 | Intentional drug misuse | FAERS: 3 | US FAERS | |
| 6 | Agranulocytosis | FAERS: 2 | US FAERS | |
| 7 | Bradycardia | FAERS: 2 | US FAERS | |
| 8 | Ileus | FAERS: 2 | US FAERS | |
| 9 | Pharmaceutical product complaint | FAERS: 2 | US FAERS | |
| 10 | Anaphylactic shock | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 11 | Blood potassium increased | FAERS: 1 | US FAERS | |
| 12 | Drug dispensing error | FAERS: 1 | US FAERS | |
| 13 | Drug exposure during pregnancy | FAERS: 1 | US FAERS | |
| 14 | Dysgeusia | FAERS: 1 | US FAERS | |
| 15 | Stillbirth | FAERS: 1 | US FAERS | |
| 16 | Suicide attempt | FAERS: 1 | US FAERS | |
| 17 | Therapeutic response delayed | FAERS: 1 | US FAERS | |
| 18 | Agitation | Canada Vigilance: 2 | Canada Vigilance | |
| 19 | Bronchospasm | Canada Vigilance: 2 | Canada Vigilance | |
| 20 | Cyanosis | Canada Vigilance: 1 | Canada Vigilance | |
| 21 | Ecchymosis | Canada Vigilance: 1 | Canada Vigilance | |
| 22 | Erythema | Canada Vigilance: 3 | Canada Vigilance | |
| 23 | Fixed eruption | Canada Vigilance: 1 | Canada Vigilance | |
| 24 | Flushing | Canada Vigilance: 1 | Canada Vigilance | |
| 25 | Headache | Canada Vigilance: 1 | Canada Vigilance | |
| 26 | Injection Site Reaction | Canada Vigilance: 2 | Canada Vigilance | |
| 27 | Laryngospasm | Canada Vigilance: 1 | Canada Vigilance | |
| 28 | Muscle Rigidity | Canada Vigilance: 1 | Canada Vigilance | |
| 29 | Pain | Canada Vigilance: 2 | Canada Vigilance | |
| 30 | Phlebitis | Canada Vigilance: 1 | Canada Vigilance | |
| 31 | Rash erythematous | Canada Vigilance: 1 | Canada Vigilance | |
| 32 | Sinus Tachycardia | Canada Vigilance: 1 | Canada Vigilance | |
| 33 | Tachycardia | Canada Vigilance: 1 | Canada Vigilance | |
| 34 | Urticaria | Canada Vigilance: 3 | Canada Vigilance | |
| 35 | Vomiting | Canada Vigilance: 1 | Canada Vigilance |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120238
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.